Pfizer (PFE) Earnings Date & Reports

Key Takeaways

• Revenue beat expectations: Pfizer posted second-quarter 2026 revenue of $15.03 billion, comfortably exceeding the Wall Street consensus estimate of approximately $14.41 billion and rising 3% from the same period a year ago.
• Adjusted earnings topped forecasts: Adjusted earnings per share (EPS) came in at $0.77, well ahead of the $0.68 analyst consensus, marking the tenth consecutive quarter Pfizer has surpassed adjusted EPS estimates.
• GAAP loss driven by impairment charge: A $4.3 billion non-cash intangible asset impairment — tied largely to the failed late-stage trial of cancer drug sigvotatug vedotin and the removal of Oxbryta revenue projections — pushed reported results to a net loss of $0.04 per share.
• Full-year revenue guidance raised: Management lifted the midpoint of its 2026 revenue outlook by $500 million to a range of $60.5 billion to $62.5 billion, while reaffirming adjusted EPS guidance of $2.80 to $3.00.
• Additional cost savings announced: Pfizer unveiled an incremental $2.5 billion in productivity savings to be realized from 2027 through 2029, bringing total targeted net savings to approximately $9.7 billion through the end of the decade.
• Non-COVID products powered growth: Excluding Comirnaty and Paxlovid, revenue grew 5% on an operational basis, with launched and acquired products surging 18% operationally.

Earnings Context and Why It Matters

Pfizer's second-quarter 2026 results arrive at a pivotal moment for the pharmaceutical giant. The company is navigating a post-pandemic transition in which COVID-19 product revenues — once an extraordinary windfall — continue to shrink rapidly, with Paxlovid sales plunging 95% and Comirnaty falling 34% year over year. At the same time, Pfizer faces a looming patent cliff for key blockbuster drugs, most notably the blood thinner Eliquis, and is under pressure to demonstrate that its pipeline and acquired assets can generate sustainable growth. This quarter was an important test of whether Pfizer's non-COVID portfolio — including oncology drugs from the $43 billion Seagen acquisition, the Vyndaqel family, and newer launches — could offset these headwinds. The results provided a meaningful positive signal, but the large impairment charge also underscored lingering pipeline risk.

Reported Results

Pfizer reported second-quarter 2026 revenue of $15.03 billion, up 3% on a reported basis and 1% on an operational basis compared to the prior-year quarter. The top-line figure sailed past the consensus estimate of roughly $14.41 billion. Adjusted diluted EPS of $0.77 exceeded analyst expectations of $0.68 by approximately 13%, continuing Pfizer's streak of adjusted earnings beats that now extends to ten consecutive quarters.

On a GAAP (Generally Accepted Accounting Principles) basis, however, Pfizer recorded a net loss of $248 million, or $0.04 per share, compared to net income of $2.91 billion, or $0.51 per share, in Q2 2025. The swing into the red was driven by $4.3 billion in non-cash intangible asset impairments, primarily reflecting the disappointing Phase III trial results for sigvotatug vedotin in previously treated non-small-cell lung cancer and the removal of revenue projections for sickle cell disease drug Oxbryta.

Segment performance was mixed but tilted positive. Primary Care revenue declined 2% operationally to $5.5 billion, weighed down by COVID products. Oncology revenue rose 2% operationally to $4.17 billion, while Specialty Care increased 7% operationally to $3.35 billion. The newly created Hospital and Biosimilars division posted revenue of $1.64 billion, down 2% operationally.

Among individual products, Eliquis was the standout, generating $2.43 billion in revenue — a 19% operational increase — significantly above analyst estimates. Padcev grew 23% operationally to $667 million, benefiting from market share gains in bladder cancer. The Vyndaqel family contributed $1.76 billion, up 8% operationally. Lorbrena rose 37% to $354 million, and Nurtec ODT/Vydura climbed 17% to $421 million. On the downside, Paxlovid revenue collapsed 95% operationally to just $21 million, while Comirnaty fell 34% to $261 million, both missing consensus estimates.

AI Screener

For investors looking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful solution. This AI-driven stock and ETF discovery tool allows traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Whether scanning for breakout candidates, trend-following setups, or fundamentally undervalued names, the AI Screener streamlines the research process and surfaces trade ideas far more efficiently than manual screening. Explore the AI Screener today to see how data-driven filtering can sharpen your market analysis.

Market Reaction and Investor Sentiment

Pfizer shares rose modestly in pre-market trading on August 4, gaining approximately 1.8% to around $25.50, following the earnings release. The relatively restrained upward move suggests that while investors welcomed the broad-based revenue beat and raised guidance, enthusiasm was tempered by the substantial impairment charge and the ongoing erosion of COVID-related revenues. The stock had been largely range-bound year-to-date, up only about 0.5% heading into the report, reflecting a market that has been in wait-and-see mode regarding Pfizer's post-pandemic growth narrative. Analysts noted that the earnings beat reflected genuine commercial strength rather than one-time factors, but emphasized that sustained positive sentiment will likely depend on upcoming pipeline catalysts — particularly in obesity and oncology — rather than quarterly execution alone.

Forward Outlook and Key Factors to Monitor

Pfizer's raised revenue guidance and reaffirmed earnings outlook signal management's confidence that non-COVID product momentum can carry through the remainder of 2026. However, several factors warrant close attention in the months ahead.

The company now expects only about $4 billion in COVID-19 product revenue for the full year, down from a prior estimate of roughly $5 billion, highlighting that pandemic-related sales remain volatile and difficult to forecast. Meanwhile, Pfizer is investing heavily in its pipeline, with adjusted research and development (R&D) spending up 12% operationally in the quarter, focused on oncology and obesity candidates. Key upcoming catalysts include late-stage data readouts for cancer drug mevrometostat and the amylin-based obesity therapy from the Metsera portfolio, as well as regulatory decisions on multiple candidates over the next twelve months.

Cost discipline remains a central theme. Pfizer now targets approximately $9.7 billion in cumulative net savings through 2029, combining cost realignment and manufacturing optimization initiatives. These savings are designed to cushion the financial impact of upcoming patent expirations, particularly for Eliquis, and to free up resources for reinvestment in growth areas.

Investors should also monitor the leadership transition in the finance function, as CFO Dave Denton departs on August 15 and veteran executive Cecile Guegan steps in as interim CFO. The search for a permanent replacement is underway. Finally, the broader regulatory landscape — including potential changes to U.S. drug pricing and reimbursement policies — could influence Pfizer's commercial outlook across its oncology and hospital portfolios.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations